Drug
NIP292
Status:
Phase 1
Condition:
Idiopathic Pulmonary Fibrosis
Intervention Type:
Oral Drug
Funder Type:
Industry
Drug Details
NIP292 is a new small-molecule drug with multiple mechanisms such as anti-inflammatory, anti-fibrosis, expansion of blood vessels, and repair of vascular endothelial damage.
Study Purpose
This study is being conducted to evaluate the safety and tolerability of single ascending and multiple ascending oral doses of NIP292 tablets administered following an overnight fast in healthy adult subjects.
Find a Clinical Trial